Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

MAB8002

Sigma-Aldrich

Anti-Hepatitis E Virus Antibody, aa 434-457, clone 1E6

clone 1E6, Chemicon®, from mouse

Synonyma:

HEV

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

1E6, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunofluorescence: suitable
western blot: suitable

isotype

IgG2b

shipped in

wet ice

Specificity

ORF2.1, encoded region to capsid protein

Immunogen

Epitope: aa 434-457

Application

Anti-Hepatitis E Virus Antibody, aa 434-457, clone 1E6 detects level of Hepatitis E Virus & has been published & validated for use in WB, ELISA & IF.
ELISA

Immunoblotting

Immunofluorescence

Optimal dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Physical form

Format: Purified
Liquid in 0.02M PB with 0.25M NaCl, pH 7.6. Contains 0.1% sodium azide.

Storage and Stability

Store at 2° to 8°C for up to 12 months from date of receipt.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Ještě jste nenalezli správný produkt?  

Vyzkoušejte náš produkt Nástroj pro výběr produktů.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Martijn D B van de Garde et al.
Journal of virology, 90(9), 4394-4401 (2016-02-19)
Genotype 3 (gt3) hepatitis E virus (HEV) infections are emerging in Western countries. Immunosuppressed patients are at risk of chronic HEV infection and progressive liver damage, but no adequate model system currently mimics this disease course. Here we explore the
Fabian Z X Lean et al.
The Journal of general virology, 103(11) (2022-11-11)
Ferrets are widely used for experimental modelling of viral infections. However, background disease in ferrets could potentially confound intended experimental interpretation. Here we report the detection of a subclinical infection of ferret hepatitis E virus (FRHEV) within a colony sub-group
Shaoli Lin et al.
Current protocols in microbiology, 48, 15L-15L (2018-03-08)
Hepatitis E virus (HEV) predominantly causes acute liver disease in humans and is transmitted via the fecal-oral route. HEV infection in pregnant women can result in grave consequences, with up to 30% fatality. The HEV strains infecting humans mainly belong
Xin Zhang et al.
Antiviral research, 216, 105670-105670 (2023-07-15)
The hepatitis E virus (HEV) is a major cause of hepatitis, with an estimated 3.3 million symptomatic cases annually. There is no HEV-specific treatment besides the off-label use of ribavirin and a vaccine is only available in China and Pakistan.
Yunlong Li et al.
Antiviral research, 184, 104967-104967 (2020-11-03)
Exposure to hepatitis E virus (HEV) bears a high risk of developing chronic infection in immunocompromised patients, including organ transplant recipients and cancer patients. We aim to identify effective anti-HEV therapies through screening and repurposing safe-in-human broad-spectrum antiviral agents. In

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.